Cardiac marker point-of-care (POC) market is expected to grow from $311m in 2016 to reach approximately $398m by 2023, according to a report by GlobalData.
Entitled MediPoint: Cardiac Markers Rapid Tests and Point of Care – Global Analysis and Market Forecasts, the report covers 15 major markets (MM) of the US, Canada, Mexico, France, Germany, Italy, Spain, Russia, the UK, Japan, China, India, South Korea, Australia, and Brazil.
Key drivers for this anticipated growth are rises in the incidence of cardiovascular disease, increased use of troponin point-of-care testing (POCT) in ambulances, and the use of cardiac market POCT in primary care.
By using troponin POCT in pre-hospital settings such as ambulances, patients can arrive at the hospital with results from a biomarker test and can be treated faster.
POCT is being used in ambulances in certain European nations, but not widely in the US due to doubts on test reliability when performed in a moving ambulance. Although, one study has demonstrated that test results are not affected.
GlobalData’s analyst covering medical devices Nadia McLurcan projects an increase in the use of POCT in ambulances in Europe to drive growth in the market. However, adoption of POCT in ambulances in the US is not expected to change significantly.
Despite the projected overall growth in the 15 major markets, a number of barriers exist. For example, management of POCT is very demanding, requiring the use of multiple devices or kits. In addition, disruptive technology is changing the working styles of medical professionals.
POC testing is usually carried out by lab technicians. It is now expected to be carried out by nurses and doctors in emergency cases, which poses a barrier in certain hospitals.